Neovista sees $18M to treat eye disorders
Neovista, a Fremont, Calif.-based biotech company specializing in eye diseases, says it raised $18 million in a fourth round of funding to commercialize its new device. The money came from Accuitive Medical Ventures, Carlyle Group, Essex Woodlands Health Ventures, MPM Capital, SV Life Sciences and Versant Ventures.
The company says the money should be enough to see the device through to approval by the Food and Drug Administration in 2010. The product has already been cleared for several European markets and will launch in Austria, Italy, Germany, Spain and the United Kingdom in May or June this year.
The device itself is used to treat age-related degeneration of certain parts of the eye. Neovista last raised funds in 2006, bringing in $41 million from the same six investors.
Next Story: Audience dials up $15M to suppress noise on cell phones
Previous Story: China syndrome: iPhone closing in on the mainland?
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.